Meropenem-Vaborbactam as Salvage Therapy for Ceftazidime-Avibactam-Resistant
Anti-Bacterial Agents
/ pharmacology
Azabicyclo Compounds
/ pharmacology
Bacteremia
/ drug therapy
Bacterial Outer Membrane Proteins
/ genetics
Bacterial Proteins
/ metabolism
Boronic Acids
/ therapeutic use
Carbapenem-Resistant Enterobacteriaceae
/ isolation & purification
Ceftazidime
/ pharmacology
Drug Combinations
Drug Resistance, Multiple, Bacterial
Hepatic Artery
/ pathology
Heterocyclic Compounds, 1-Ring
/ therapeutic use
Humans
Klebsiella Infections
/ drug therapy
Klebsiella pneumoniae
/ drug effects
Liver Transplantation
/ adverse effects
Male
Meropenem
/ therapeutic use
Microbial Sensitivity Tests
Salvage Therapy
/ methods
Thrombosis
/ pathology
Young Adult
beta-Lactamases
/ metabolism
Klebsiella pneumoniae carbapenemase
carbapenem-resistant Enterobacteriaceae
carbapenemase-producing Klebsiella pneumoniae
ceftazidime-avibactam
meropenem-vaborbactam
Journal
Antimicrobial agents and chemotherapy
ISSN: 1098-6596
Titre abrégé: Antimicrob Agents Chemother
Pays: United States
ID NLM: 0315061
Informations de publication
Date de publication:
01 2019
01 2019
Historique:
entrez:
23
12
2018
pubmed:
24
12
2018
medline:
19
12
2019
Statut:
epublish
Résumé
We report a case of a 24-year-old liver transplant recipient who developed hepatic artery thrombosis and graft failure, which was complicated by subphrenic abscess and persistent
Identifiants
pubmed: 30578403
pii: AAC.01551-18
doi: 10.1128/AAC.01551-18
pmc: PMC6325210
pii:
doi:
Substances chimiques
Anti-Bacterial Agents
0
Azabicyclo Compounds
0
Bacterial Outer Membrane Proteins
0
Bacterial Proteins
0
Boronic Acids
0
Drug Combinations
0
Heterocyclic Compounds, 1-Ring
0
avibactam, ceftazidime drug combination
0
meropenem and vaborbactam
0
Ceftazidime
9M416Z9QNR
beta-Lactamases
EC 3.5.2.6
carbapenemase
EC 3.5.2.6
Meropenem
FV9J3JU8B1
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2018 American Society for Microbiology.
Références
Antimicrob Agents Chemother. 2009 Aug;53(8):3365-70
pubmed: 19506063
Clin Infect Dis. 2016 Sep 15;63(6):754-762
pubmed: 27313268
mBio. 2017 Oct 31;8(5):
pubmed: 29089425
Antimicrob Agents Chemother. 2017 Jun 27;61(7):
pubmed: 28461318
Diagn Microbiol Infect Dis. 2013 Feb;75(2):115-20
pubmed: 23290507
Lancet Infect Dis. 2018 Apr;18(4):391-400
pubmed: 29456043
J Antimicrob Chemother. 2018 Apr 1;73(4):953-961
pubmed: 29377998
J Antimicrob Chemother. 2015 Jul;70(7):2133-43
pubmed: 25900159
Antimicrob Agents Chemother. 2018 Apr 26;62(5):
pubmed: 29507064
Antimicrob Agents Chemother. 2018 Feb 23;62(3):
pubmed: 29263067
Antimicrob Agents Chemother. 2017 Feb 23;61(3):
pubmed: 28031201
Antimicrob Agents Chemother. 2017 Apr 24;61(5):
pubmed: 28223379
J Antimicrob Chemother. 2015 Aug;70(8):2279-86
pubmed: 25957381
Int J Antimicrob Agents. 2018 Aug;52(2):144-150
pubmed: 29510189
Infect Control Hosp Epidemiol. 2013 Jan;34(1):1-14
pubmed: 23221186
Antimicrob Agents Chemother. 2014;58(4):2322-8
pubmed: 24514083
Clin Infect Dis. 2016 Dec 15;63(12):1615-1618
pubmed: 27624958
Antimicrob Agents Chemother. 2017 Nov 22;61(12):
pubmed: 29038260
Lancet Infect Dis. 2016 Jun;16(6):661-673
pubmed: 27107460
J Antimicrob Chemother. 2018 Jun 1;73(6):1525-1529
pubmed: 29566151
Clin Infect Dis. 2018 Jan 6;66(2):163-171
pubmed: 29020404
JAMA. 2018 Feb 27;319(8):788-799
pubmed: 29486041